A Molecular Imaging Paradigm to Rapidly Profile Response to Angiogenesis-directed Therapy in Small Animals

Virostko, John; Xie, Jingping; Hallahan, Dennis E.; Arteaga, Carlos L.; Gore, John C.; Manning, H. Charles

doi:10.1007/s11307-008-0193-9

Cited by 20 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different noninvasive imaging modalities have been applied for the monitoring of the response to angiogenesisdirected therapies. [12][13][14][15] The information provided by molecular imaging combined with the assessment of tumor perfusion will likely prove useful in characterizing a tumor's phenotype, detecting metastases, monitoring tumor response to therapy, and for finding the optimal time window for treatments and dose ranging of anticancer drugs.…”

mentioning

confidence: 99%

BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis

Pochon¹,

Tardy²,

Bussat³

et al. 2010

Investigative Radiology

243

189

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis

Pochon¹,

Tardy²,

Bussat³

et al. 2010

Investigative Radiology

243

189

View full text Add to dashboard Cite

show abstract

“…248 It is here where in vivo imaging may illuminate the key mechanisms and bridge the gap between success in animal and failure in human trials and several recent publications support this hypothesis. Although numerous studies are using molecular imaging as a technique to qualitatively assess and quantify the efficacy of angiogenic treatment, [249][250][251][252] we will focus on some examples, where imaging is combined with therapy.…”

Section: Combined Imaging and Therapymentioning

confidence: 99%

In vivo small animal imaging: Current status and future prospects

et al. 2010

View full text Add to dashboard Cite

The use of small animal models in basic and preclinical sciences constitutes an integral part of testing new pharmaceutical agents prior to commercial translation to clinical practice. Whole-body small animal imaging is a particularly elegant and cost-effective experimental platform for the timely validation and commercialization of novel agents from the bench to the bedside. Biomedical imaging is now listed along with genomics, proteomics, and metabolomics as an integral part of biological and medical sciences. Miniaturized versions of clinical diagnostic modalities, including but not limited to microcomputed tomography, micromagnetic resonance tomography, microsinglephoton-emission tomography, micropositron-emission tomography, optical imaging, digital angiography, and ultrasound, have all greatly improved our investigative abilities to longitudinally study various experimental models of human disease in mice and rodents. After an exhaustive literature search, the authors present a concise and critical review of in vivo small animal imaging, focusing on currently available modalities as well as emerging imaging technologies on one side and molecularly targeted contrast agents on the other. Aforementioned scientific topics are analyzed in the context of cancer angiogenesis and innovative antiangiogenic strategies under-the-way to the clinic. Proposed hybrid approaches for diagnosis and targeted site-specific therapy are highlighted to offer an intriguing glimpse of the future.

show abstract

“…Tumor fluorescence intensity was quantified and normalized after autofluorescence removal. This study demonstrates that MSFI provides rapid, noninvasive, and longitudinal assessment of the efficacy of novel angiogenesis-directed therapies in preclinical models of cancer (11). To overcome constraints associated with exogenously administered vascular imaging probes such as high cost, toxicity, inconsistent delivery, differential bioavailability among animals, and high tumor accumulation resulting from vessel leakiness, a novel method to noninvasively image tumor vascularization in fluorescent tumors without exogenous imaging probes was introduced.…”

Section: Preclinical Application Of Mfsi To Assess Tumor Vascularizatmentioning

confidence: 99%

Multispectral Fluorescence Imaging

Zhou

El‐Deiry²

2009

J Nucl Med

View full text Add to dashboard Cite

Multispectral fluorescence imaging (MSFI) is a rapidly growing field with broad applications in both preclinical and clinical settings. Application of this novel technology in small-animal imaging and microscopy produces enhanced sensitivity and reliable quantification and resolves multiple simultaneous signals. MSFI flow cytometry can quantify multiple fluorescent parameters with morphologic or subcellular spatial details on millions of cells. MSFI has the potential to improve the accuracy of disease detection or differentiation and intrasurgical metastatic diagnosis, guide neurosurgeries, and monitor treatment response.Key Words: multispectral fluorescence imaging; multiplexing; spectral unmixing; small-animal imaging; microscopy; flow cytometry Multispectral imaging (MSI) is the synergistic combination of imaging and spectroscopy. Color is the appearance of a light most affected by wavelength (l) and the observers' visual system. Objects with similar colors are not necessarily the same. The simplest example is the spectrally pure yellow and the mixture of red and green, which have completely different spectral content but precisely the same redgreen-blue (RGB) coordinates (1). Spectroscopy is the technique of breaking light down into its composite colors to identify the composition of the object. Distinguished from conventional RGB full-color imaging, MSI can obtain a high-resolution optical spectrum for each image pixel, resulting in a series of images of the same field of view that are acquired at different wavelengths. These can be stacked in 3-dimensional datasets or a cube (x, y, and l). After proper calibration, quantitative images of individual analytes can be generated. Excellent reviews of MSI instrumentation and data analysis exist (1,2). Briefly, a camera is used to acquire the spatial information, and the spectral information is gained by scanning a dispersive element to record spectra for each image. Electronic tunable filters such as an acousto-optic tunable filter and liquid crystal tunable filters (LCTFs) are preferable to mechanically scanning dispersive devices (filter wheels, monochromators) because they are quiet, fast, compact, and stable and demonstrate increased spectral selectivity, spectral purity, and flexibility. The disadvantages of electronic tunable filters include low light throughput, photobleaching, and inappropriate capture if significant sample or camera movement occurs during the acquisition or if high temporal resolution is needed to capture certain events (e.g., calcium signaling transients) (3). The typical method for data analysis of MSI is a least-squares-fitting linear unmixing approach with additional constraints (such as nonnegativity), resulting component images, and a final composite image. This approach is limited to spectral analysis only, whereas combining the rich spatial information in the images with the spectral data is a more powerful and evolving field (1). Multispectral fluorescence imaging (MSFI) coupled with microscopy and flow cytometry are commercial...

show abstract

A Molecular Imaging Paradigm to Rapidly Profile Response to Angiogenesis-directed Therapy in Small Animals

Cited by 20 publications

References 30 publications

BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis

BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis

In vivo small animal imaging: Current status and future prospects

Multispectral Fluorescence Imaging

Contact Info

Product

Resources

About